IPP Bureau
Lupin signs deal with Axantia to market pegfilgrastim in Middle East and Africa
By IPP Bureau - February 01, 2022
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Medix Biochemica acquires myPOLS Biotec to expand its molecular diagnostics business
By IPP Bureau - February 01, 2022
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
By IPP Bureau - February 01, 2022
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
CAS launches major biology expansion
By IPP Bureau - February 01, 2022
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
Alembic receives USFDA approval for clarithromycin tablets
By IPP Bureau - February 01, 2022
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
Budget 22-23: Healthcare sector applauds focus on mental health
By IPP Bureau - February 01, 2022
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Pharma industry seeks fiscal support to drive innovation
By IPP Bureau - January 31, 2022
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
By IPP Bureau - January 31, 2022
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
USFDA approves Genentech’s Vabysmo to treat causes of vision loss
By IPP Bureau - January 31, 2022
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
DRiefcase app for Ayushman Bharat Digital Mission
By IPP Bureau - January 31, 2022
ABDM is a digital framework that will connect patients, doctors and other healthcare stakeholders nationwide to facilitate safe and secure movement of health information
Granules Pharmaceuticals concludes USFDA audit with three minor observations
By IPP Bureau - January 31, 2022
The audit is a PAI for two of its product applications filed from this facility
Cipla has strong traction in India and the US: ICICI Direct
By IPP Bureau - January 31, 2022
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
By IPP Bureau - January 31, 2022
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Alkem enters exclusive license agreement with Johns Hopkins University
By IPP Bureau - January 31, 2022
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
By IPP Bureau - January 31, 2022
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
